AMRX · Amneal Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$21.38
-0.32 (-1.47%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.45B
Shares
348.41M
Volume · Nov 13
1.72M
Avg daily vol (3M)
3.17M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Amneal Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Amneal Pharmaceuticals, Inc. (AMRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Revenue
$862.68M
▲ 10% YoY Diluted EPS
$-0.06
▼ 700% YoY Gross margin
38.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-30
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Confident tone
Biosimilars / Kashiv acquisition
Affordable medicines / transdermal patches
Specialty brands
Revenue
$796.20M
▲ 9.9% YoY Diluted EPS
$0.18
▲ 157.1% YoY Gross margin
42.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Amneal Pharmaceuticals, Inc. (AMRX) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-22
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Confident tone
Kashiv Acquisition
Biosimilars Market Opportunity
Q1 2026 Financial Results
Revenue
$722.52M
▲ 3.9% YoY Diluted EPS
$0.19
▲ 375% YoY Gross margin
44.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Amneal Pharmaceuticals, Inc. (AMRX) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-27
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Confident tone
Specialty / Crexone (Krexone) Parkinson's launch
Affordable Medicines / Complex Generics
Biosimilars
Revenue
$814.32M*
▲ 11.5% YoY Gross margin
36.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
Confident tone
Biosimilars pipeline
GLP-1 collaboration with Metsera
CREXONT (Parkinson's disease)
Revenue
$784.51M
▲ 11.7% YoY Diluted EPS
$0.01
Gross margin
34.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript
Confident tone
CREXONT Parkinson's launch
Brekiya autoinjector launch
Affordable Medicines / injectables
Revenue
$724.51M
▲ 3.2% YoY Diluted EPS
$0.07
▲ 250% YoY Gross margin
39.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-02
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
Confident tone
Affordable Medicines / injectables and biosimilars
CREXONT launch momentum and market access
U.S. manufacturing footprint and tariffs
Revenue
$695.42M
▲ 5.5% YoY Diluted EPS
$0.04
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript
Confident tone
Crexent launch and specialty growth
Biosimilars pipeline
GLP-1 / Medcera weight loss collaboration
Revenue
$730.52M*
▲ 18.4% YoY Gross margin
36.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
Confident tone
CREXONT launch (Parkinson's)
GLP-1 / Obesity (Metsera collaboration)
Affordable Medicines / Generic segment
Revenue
$702.47M
▲ 13.3% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
38.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript
Confident tone
Affordable Medicines / Generic segment growth
CREXONT approval and launch
Biosimilars pipeline and expansion
Revenue
$701.78M
▲ 17.1% YoY Diluted EPS
$0.02
▼ 75% YoY Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-03
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript
Confident tone
Specialty / Neurology Pipeline
Biosimilars Opportunity
Injectables and Drug Shortages
Revenue
$659.19M
▲ 18.2% YoY Diluted EPS
$-0.30
Gross margin
36.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
Confident tone
Specialty / Neurology Pipeline
Generics and Injectables Growth
Biosimilars Expansion
Revenue
$616.98M*
▲ 1.2% YoY Gross margin
30.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript
Revenue
$620.04M
▲ 13.7% YoY Diluted EPS
$0.06
Gross margin
37.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-04
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Call Transcript
Revenue
$599.05M
▲ 7.1% YoY Diluted EPS
$0.08
Gross margin
36.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Call Transcript
Revenue
$557.54M
▲ 12% YoY Diluted EPS
$-0.05
Gross margin
32.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2022 Earnings Call Transcript
Revenue
$609.76M*
▲ 13.6% YoY Gross margin
35.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-04
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Call Transcript
Revenue
$545.56M
▲ 3.2% YoY Diluted EPS
$-0.02
Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2022 Earnings Call Transcript
Revenue
$559.36M
▲ 4.5% YoY Diluted EPS
$-0.80
▼ 900% YoY Gross margin
35.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2022 Earnings Call Transcript
Revenue
$497.63M
▲ 0.9% YoY Diluted EPS
$-0.01
▼ 125% YoY Gross margin
35.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-02
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2021 Earnings Call Transcript
Revenue
$536.90M*
▲ 5.3% YoY Gross margin
31.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2021 Earnings Call Transcript
Revenue
$528.59M
▲ 1.8% YoY Diluted EPS
$-0.03
Gross margin
37.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2021 Earnings Call Transcript
Revenue
$535.08M
▲ 15.2% YoY Diluted EPS
$0.10
Gross margin
39.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcript
Revenue
$493.11M
▼ 1.1% YoY Diluted EPS
$0.04
▼ 94.9% YoY Gross margin
38.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-26
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call Transcript
Revenue
$510.03M*
▲ 28.4% YoY Gross margin
32.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2020 Earnings Call Transcript
Revenue
$519.29M
▲ 37.3% YoY Diluted EPS
$-0.06
Gross margin
25.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2020 Earnings Call Transcript
Revenue
$464.66M
▲ 14.8% YoY Diluted EPS
$-0.08
Gross margin
31.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2020 Earnings Call Transcript
Revenue
$498.53M
▲ 11.7% YoY Diluted EPS
$0.78
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2019 Earnings Call
Revenue
$397.33M
▼ 20.1% YoY Diluted EPS
$-0.23
Gross margin
27.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 webcasts
Key facts
CIK
1723128
CUSIP
03168L105
13F (30d)
271 filings
247 filers
Visit website
Investor relations